Repetitive intravenous dihydroergotamine as therapy for intractable migraine

Neurology. 1986 Jul;36(7):995-7. doi: 10.1212/wnl.36.7.995.

Abstract

For patients with chronic intractable headache, we compared a new treatment and a traditional one. Fifty-five patients (36 dependent on ergotamine, analgesics, diazepam, or corticosteroids) were given IV dihydroergotamine (DHE) and metoclopramide every 8 hours. Fifty-four age- and sex-matched patients (38 drug-dependent) were given diazepam intravenously every 8 hours. Forty-nine of the 55 DHE-treated patients became headache-free within 48 hours, and 39 of them sustained benefits in a mean follow-up of 16 months. In contrast, 7 diazepam-treated patients became free of headache within 3 to 6 days, and 31 had improved somewhat in 10 days. Repetitive IV DHE helps to terminate cycles of intractable migraine.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Chronic Disease
  • Clinical Trials as Topic
  • Diazepam / therapeutic use
  • Dihydroergotamine / administration & dosage
  • Dihydroergotamine / therapeutic use*
  • Female
  • Humans
  • Injections
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Migraine Disorders / drug therapy*
  • Suppositories
  • Time Factors

Substances

  • Suppositories
  • Dihydroergotamine
  • Diazepam